LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

LLY

744.73

-1.3%↓

JNJ

177.09

-0.56%↓

ABBV

214.89

-1.56%↓

UNH

348.74

-1.18%↓

AZN

77.76

-2.24%↓

Search

BioMarin Pharmaceutical Inc

Open

SectorHealthcare

53.17 -1.74

Overview

Share price change

24h

Current

Min

52.93

Max

54.23

Key metrics

By Trading Economics

Income

241M

426M

Sales

80M

825M

P/E

Sector Avg

16.631

35.664

EPS

1.44

Profit margin

51.637

Employees

3,040

EBITDA

95M

319M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+82.27% upside

Dividends

By Dow Jones

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-740M

11B

Previous open

54.91

Previous close

53.17

News Sentiment

By Acuity

100%

0%

356 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2025, 22:41 UTC

Major Market Movers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 Sept 2025, 16:04 UTC

Major Market Movers

Upexi Shares Climb on Solana Gains

14 Sept 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 Sept 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 Sept 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 Sept 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14 Sept 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 Sept 2025, 08:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 20:09 UTC

Earnings

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 Sept 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 Sept 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 Sept 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 Sept 2025, 18:38 UTC

Market Talk
Earnings

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 Sept 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 Sept 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 Sept 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 Sept 2025, 16:22 UTC

Earnings

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 Sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Sept 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 Sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 Sept 2025, 16:11 UTC

Earnings

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 Sept 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 Sept 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 Sept 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer Comparison

Price change

BioMarin Pharmaceutical Inc Forecast

Price Target

By TipRanks

82.27% upside

12 Months Forecast

Average 98.59 USD  82.27%

High 122 USD

Low 60 USD

Based on 24 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

20

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

59.405 / 62.19Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

356 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat